Dear ALSP Community Members,

As announced in our press release earlier today, after reviewing the final data analysis from the IGNITE Phase 2 trial, we determined that no beneficial effects on biomarkers or clinical endpoints were observed in CSF1R-ALSP patients treated with iluzanebart (VGL101). Iluzanebart demonstrated a favourable safety and tolerability profile. Due to lack of efficacy, the Phase 2 IGNITE long-term extension study, and the ILLUMINATE Natural History Study will be discontinued.

We recognize that this is very difficult news. We want to express our heartfelt gratitude to the ALSP community for your incredible support and partnership over the past five years. We are especially thankful to all study participants and their families—your contributions have been invaluable. Vigil remains committed to ensuring appropriate follow-up and support are provided as the studies wind down.

Because of your dedication and participation, the field is now better positioned for future research and clinical trials. Significant progress has been made in understanding relevant outcome measures and biomarkers, which will help guide future drug development efforts for CSF1R-ALSP. Importantly, regulatory agencies in the US, UK, and EU have also gained greater awareness of the devastating impact of ALSP and the urgent need for effective therapies.

We would like to extend our deep appreciation to the outstanding patient advocacy organizations for their unwavering support and collaboration, including the Sisters' Hope Foundation, United Leukodystrophy Foundation, Hunter's Hope Foundation, and Alex TLC.

Study participants and their families are encouraged to contact their study physician for all personalized information or questions.

I am also available to answer any additional questions that you may have.

With my heartfelt gratitude,

Cynthia Cassandro

VP, Patient Advocacy